Novavax (NVAX) stock trades up, here is why
Novavax (NVAX) shares rose 8.8% after reporting Q3 2026 revenue of $68M and raising its full-year revenue outlook to $400M midpoint. The company also received a $125M milestone payment. NVAX reported a net loss of $31M, narrower than the prior year's $202M loss. The stock is up 49.4% YTD but remains 16.9% below its 52-week high.
How this was made

The 30-second read
Why it matters
The earnings beat and guidance raise provide fresh material for traders, indicating short‑term upside potential.
Market read
The earnings release is the primary catalyst for the stock's move, offering a clear trading signal.
What to watch
Potential regulatory or manufacturing delays could temper the upside.
Background
Novavax disclosed its Q3 2026 financials and raised its full‑year revenue guidance, prompting an 8.8% share rise.
Ticker impact
Novavax reported Q3 2026 results, raised full-year revenue outlook to $400M and received a $125M milestone, driving an 8.8% share jump.
likely upward pressure as the market prices in the higher revenue outlook
Revenue guidance increase of $145M and a sizable milestone payment are material new facts that moved the stock 8.8% intraday.
Market effects
Biotech sector may see modest uplift as vaccine earnings beat expectations.
U.S. biotech stocks could benefit from the positive earnings surprise.
Limited to vaccine developers; no broad macro impact.
Counterpoint
The revenue outlook remains modest; investors may be cautious about long‑term growth.
Key entities
- companyNovavax
Vaccine biotechnology firm reporting Q3 results.
- partnerSanofi
Initiated Phase 3 combination vaccine trial, triggering a $125M milestone for Novavax.




